TRexBio Announces Closing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the closing of its initial public offering of 8,333,334 shares of its common stock at the initial public offering price of $14.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $116.7 million. All of the shares were sold by TRexBio. TRexBio’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “TRXB”.

J.P. Morgan, Evercore ISI, Cantor, and Stifel are acting as lead book-running managers for the offering. Wedbush PacGrow is acting as book-running manager for the offering.